Results showed the median ABR for all bleeds was reduced by 54.7%. The Food and Drug Administration (FDA) has approved Vonvendi ® (von Willebrand factor [recombinant]) for routine prophylaxis to ...
Could your heavy flow be cause for concern? Sherri Ozawa, MSN, RN, tells The Post that serious blood loss during menstruation could be a symptom of von Willebrand disease, a blood disorder that ...
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK, TKPHF, 4502.T) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
Findings showed that routine prophylaxis with wilate resulted in an 84% reduction in mean total ABRs compared with on-demand treatment. The Food and Drug Administration (FDA) has expanded the approval ...
Vonvendi is a lab-made version of von Willebrand factor (VWF), a protein your body needs for blood to clot. Affecting more than 3 million people in the U.S, von Willebrand disease (VWD) is a common ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical ...
DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts ...
Despite expectations to the contrary, treatment with recombinant von Willebrand factor (VWF) was not superior to tranexamic acid (TXA) for managing heavy menstrual bleeding in women with mild or ...
The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) have developed ...
New research by RCSI University of Medicine and Health Sciences published in Blood journal has revealed that the age at which individuals are tested for von Willebrand disease (VWD), a common bleeding ...
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) said that the U.S. Food & Drug Administration approved Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results